O verweight individuals with a BMI 27 kg/m and at least one weight-related comorbidity (such as hypertension, hyperlipidemia, type 2 diabetes, sleep apnea, etc.)
Orforglipron (Eli Lilly) Orforglipron is a first-in-class, nonpeptide oral GLP-1 receptor agonist
That puts me in an interesting position
As long as you are in good general health then you can consider fat-dissolving treatment after consultation with one of our aesthetic treatment experts
What this means for patients: GLP-1 medications may result in a lower cancer risk in addition to supporting weight loss and diabetes control
However, this review also noted that the quality of the studies was not very high, so more studies are needed before its possible to make any firm recommendations